StockData
BeOne Medicines Ltd. logo

BeOne Medicines Ltd. (ONC) operating KPIs

ONCNasdaqPharmaceutical PreparationsFiscal year ends December 31Also trades as BEIGF
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 12/302313% above fair value
$370.33−1.23 (-0.33%)

Close on Oct 30, 2026Market cap $42.11BP/E 66.2Yield –

BeOne Medicines amgen In-Licensed Products — Total Net Product Revenue ($M) ($M)

Form 10-Q / 10-K MD&A & Segment Disaggregation Note (XBRL)

QuarterlyAnnual
Latest, Q2 2026
157
Period ended Jun 30, 2026
Change on a year earlier
+24.5%
126 in Q2 2025
History
11 quarters
Since Q2 2023
Sources
8
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedAmgen In-Licensed Products — Total Net Product Revenue ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026157+24.5%Form 10-Q (filed 2026-08-05) ↗
Q1 2026Mar 31, 2026142+24.5%Form 8-K (filed 2026-05-06) ↗
Q4 2025Dec 31, 2025112–Form 8-K (filed 2026-02-26) ↗
Q3 2025Sep 30, 2025133+31.0%Form 10-Q (filed 2025-11-06) ↗
Q2 2025Jun 30, 2025126+40.2%Form 10-Q (filed 2025-08-06) ↗
Q1 2025Mar 31, 2025114+58.7%Form 10-Q (filed 2025-05-07) ↗
Q3 2024Sep 30, 2024102+101.6%Form 10-Q (filed 2024-11-12) ↗
Q2 2024Jun 30, 202490.1+81.7%Form 10-Q (filed 2024-08-07) ↗
Q1 2024Mar 31, 202471.9–Form 10-Q (filed 2025-05-07) ↗
Q3 2023Sep 30, 202350.4–Form 10-Q (filed 2024-11-12) ↗
Q2 2023Jun 30, 202349.6–Form 10-Q (filed 2024-08-07) ↗

Breakdown

What makes up amgen in-licensed products — total net product revenue ($m)

Cite this data

StockData. (2026). BeOne Medicines Amgen In-Licensed Products — Total Net Product Revenue ($M) ($M), quarterly Q2 2023–Q2 2026 [Data set]. Compiled from BeOne Medicines SEC filings and investor materials. https://stockdatahq.com/stocks/onc/kpis/prod_amgen_tot

See every metric in the BeOne Medicines KPI table. Data updated Oct 29, 2026.